Company news

Unicycive Therapeutics, Inc. news in 2024

Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

December 16, 2024

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

November 20, 2024

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

November 10, 2024

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

October 27, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

October 15, 2024

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

October 13, 2024

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

October 8, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

September 23, 2024

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

September 15, 2024

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

September 2, 2024

Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

August 25, 2024

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

July 16, 2024

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

July 10, 2024

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

July 9, 2024

Unicycive Therapeutics Joins Russell Microcap® Index

June 30, 2024

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

June 24, 2024

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

May 27, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

May 22, 2024

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

May 14, 2024

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

May 12, 2024

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

April 9, 2024

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

March 27, 2024

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

March 24, 2024

Unicycive Announces $50 Million Private Placement

March 13, 2024

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

March 12, 2024

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

March 6, 2024

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

March 3, 2024

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

February 13, 2024

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

January 28, 2024

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

January 22, 2024

Decks in 2024